Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cybin Inc (CYBN.NE)

Cybin Inc (CYBN.NE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NEO]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NEO]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 280,630
  • Shares Outstanding, K 161,366
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.84
Trade CYBN.NE with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.36
  • Most Recent Earnings -0.11 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.560 +14.10%
on 12/03/21
3.000 -40.67%
on 11/08/21
-0.520 (-22.61%)
since 11/03/21
3-Month
1.560 +14.10%
on 12/03/21
3.350 -46.87%
on 09/07/21
-1.490 (-45.57%)
since 09/03/21
52-Week
1.070 +66.36%
on 12/04/20
4.000 -55.50%
on 07/27/21
+0.720 (+67.92%)
since 12/03/20

Most Recent Stories

More News
Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that...

CYBN.NE : 1.780 (+1.71%)
CYBN : 1.3900 (unch)
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that the...

CYBN.NE : 1.780 (+1.71%)
CYBN : 1.3900 (unch)
Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that...

CYBN.NE : 1.780 (+1.71%)
CYBN : 1.3900 (unch)
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced it has awarded...

CYBN.NE : 1.780 (+1.71%)
CYBN : 1.3900 (unch)
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today reported unaudited...

CYBN.NE : 1.780 (+1.71%)
CYBN : 1.3900 (unch)
Cybin to Present at the Jefferies London Healthcare Conference

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that...

CYBN.NE : 1.780 (+1.71%)
CYBN : 1.3900 (unch)
Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” today announced that it will...

CYBN.NE : 1.780 (+1.71%)
CYBN : 1.3900 (unch)
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced positive...

CYBN.NE : 1.780 (+1.71%)
CYBN : 1.3900 (unch)
Increasing Prevalence of Depression & Mental Health Disorders Fueling Huge Growth in Psychedelic Drugs Market

Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary  – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To...

CYBN.NE : 1.780 (+1.71%)
MCUR.CN : 0.230 (unch)
MCURF : 0.1778 (-4.56%)
CYBN : 1.3900 (unch)
LKYSF : 0.4800 (-3.63%)
NUMI.VN : 0.550 (unch)
ATAI : 10.58 (-5.03%)
CMPS : 29.60 (-7.36%)
Cybin Granted DEA Schedule I Manufacturing License

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced that the...

CYBN.NE : 1.780 (+1.71%)
CYBN : 1.3900 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 2.090
2nd Resistance Point 1.940
1st Resistance Point 1.860
Last Price 1.780
1st Support Level 1.630
2nd Support Level 1.480
3rd Support Level 1.400

See More

52-Week High 4.000
Fibonacci 61.8% 2.881
Fibonacci 50% 2.535
Fibonacci 38.2% 2.189
Last Price 1.780
52-Week Low 1.070

See More

Business Summary

Cybin Inc is a life sciences company. The company is focused on psychedelic drug development, delivery mechanisms, improved novel compounds and protocols that target psychiatric and neurological diseases.

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar